ZYNE is currently covered by 1 analysts with average potential upside of $6.82 (77.16%) backed by 37 price targets and 38 ratings. Documented since 31-Aug-2015. Analyst's average stock valuation to be materialised ratio is 29.76% with an average time for price targets to be met of 152.33 days.
Most recent stock forecast was given by CHARLES DUNCAN from CANTOR FITZGERALD on 06-May-2021.
Highest price target for ZYNE is 4, Lowest price target is 4, average price target is 4.
Currently, out of the existing stock ratings of ZYNE - 1 which are a Buy (100%)
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average time for PT to be met
Performance score
Buy
8
$7.59 (1851.22%)
22
1 years 10 months 22 days ago
1/6 (16.67%)
$7.13 (63.45%)
2
Buy
8
$7.59 (1851.22%)
11
2 years 18 days ago
0/4 (0%)
$5.67 (126.55%)
Buy
12
$11.59 (2826.83%)
18
2 years 8 months 27 days ago
2/7 (28.57%)
$8.77 (155.76%)
316
Hold
11
$10.59 (2582.93%)
7
3 years 6 months 12 days ago
2/4 (50%)
$4.6 (23.96%)
23
Buy
17
4 years 6 months 7 days ago
1/6 (16.67%)
$7.54 (47.36%)
498
What is ZYNE(Zynerba Pharmaceuticals, Inc) average time for price targets to be met?
Which analyst has the current highest performing score on ZYNE(Zynerba Pharmaceuticals, Inc) with a proven track record?
